Explore the NIHProtocol Details
The Efficacy of 17Beta-Estradiol in Postpartum-Related Depressive Illness
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
03-M-0161 |
Sponsoring Institute |
National Institute of Mental Health (NIMH) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
No |
Population Exclusion(s) |
Children; |
Special Instructions |
Currently Not Provided |
Keywords |
Pregnancy; |
Recruitment Keyword(s) |
Postpartum Depression |
Condition(s) |
Postpartum Depression; |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
Drug: 17 beta-estradiol |
Supporting Site |
|
PPD causes significant distress to a large number of women; the demand for effective therapies to treat PPD is considerable. Estradiol therapy has a prophylactic effect in women at high risk for developing PPD. The prevention of a decline in estradiol levels may prevent the onset of PPD. Studies also suggest that estradiol has antidepressant effects in women and may provide a safe and effective alternative to traditional antidepressants in women with PPD.
Participants will be screened with a medical history, physical examination, blood and urine tests, psychological tests, genetic studies, and self-rating scales and questionnaires. Upon study entry, women will be randomly assigned to wear skin patches containing either estradiol or placebo (a patch with no active ingredient) for 6 weeks. Women who receive estradiol and do not menstruate during the last week of the study will receive progesterone for 7 days to initiate menstruation. Women who receive placebo and do not menstruate during the last week of the study will continue to receive placebo at the end of the study. Every week, participants will have blood taken and will be asked to complete symptom self-rating scales. A urine sample and blood samples will be collected at different time points through out of the study. Participants who receive placebo and those whose symptoms do not improve with estradiol therapy will be offered treatment with standard antidepressant medications for 8 weeks at the end of the study.
Eligibility
INCLUSION CRITERIA:
Subjects for this study will meet the following criteria:
1) A history of at least two weeks with postpartum-related mood disturbances of moderate severity, and self-report of the onset of depression within three months of a normal vaginal delivery or uncomplicated Caesarean section;
2) A current episode of minor (meeting 3-4 criterion symptoms) or major depression (of moderate severity or less on the SCID severity scale and not meeting DSM-IV criteria symptom 9 [suicidal ideation]) as determined by the administration of the minor depression module of the SADS-L and the Structured Clinical Interview for DSM-IV. Additionally, to ensure that subjects meet a minimum threshold for severity of depression, subjects will have scores greater than or equal to 10 on either the Beck Depression Inventory (BDI) or the Center for Epidemiologic Studies - Depression (CES-D) Scale during at least three of the six clinic visits during the two week screening phase, as well as a 17 item Hamilton Depression score greater than or equal to 10. Subjects will be excluded if they meet any of the following criteria: major depression of greater than moderate severity (including postpartum psychosis). DSM-IV criteria #9 (suicidal ideation), or anyone requiring immediate treatment after clinical assessment.
3) Not greater than six months post delivery;
4) Age 20 to 45;
5.) No prior hormonal therapy for the treatment of postpartum-related mood or physical symptoms within the last six months;
6) No history of psychiatric illness during the two years prior to the reported onset of the current episode of depression;
7) In good medical health, and not taking any medication or dietary and herbal supplements on a regular basis (with the exception of multivitamins or calcium supplements).
EXCLUSION CRITERIA:
The following conditions will constitute contraindications to treatment and will preclude a subject's participation in this protocol:
1) severe major depression with any of the following:
1. positive (threshold) response to SCID major depression section item # 9, suicidal ideation;
2. anyone requiring immediate treatment after clinical assessment;
3. severity ratings greater than moderate on the SCID IV interview (including postpartum psychosis);
2) current treatment with antidepressant medications
3) history of psychiatric illness during the two years before the reported onset of the current episode of depression or a history of either mania (DSM-IV criteria) or postpartum psychosis at any time in the past.
4) history of ischemic cardiac disease, pulmonary embolism, retinal thrombosis, or thrombophlebitis; any subject with risk factors for thrombo-embolic phenomena including cigarette smokers (greater than 10 cigarettes per day), varicose veins, patients with prolonged periods of immobilization (including prolonged travel), and active heart disease.
5) renal disease, asthma
6) hepatic dysfunction
7) women with a history of carcinoma of the breast, or women with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first degree relative; multiple family members (greater than three relatives) with postmenopausal breast cancer
8) women with a history of uterine cancer, endometriosis, ill-defined pelvic lesions, particularly undiagnosed ovarian enlargement, undiagnosed vaginal bleeding
9) patients with a known hypersensitivity of estradiol, Alora, or medroxyprogesterone acetate
10) pregnant women
11) porphyria
12) diabetes mellitus
13) cholecystitis or pancreatitis
14) history of cerebrovascular disease (stroke), epilepsy, hypertension, hypercalcemia
15) recurrent migraine headaches
16) malignant melanoma
17) history of familial hyperlipoproteinemia
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information http://clinicalstudies.info.nih.gov. |
| Peter J. Schmidt, M.D. National Institute of Mental Health (NIMH) National Institutes of Health Building 10 Room 7-3342 10 Center Drive Bethesda, Maryland 20892 (301) 594-6561 apudj@mail.nih.gov |
Peter J. Schmidt, M.D. National Institute of Mental Health (NIMH) National Institutes of Health Building 10 Room 7-3341 10 Center Drive Bethesda, Maryland 20892 (301) 435-7644 decothk@mail.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00059228
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
